methyl 3-(isopropoxyhydrophosphoryl)propanoate | 1255533-69-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: methyl 3-(isopropoxyhydrophosphoryl)propanoate
• CAS: 1255533-69-7
• 化学式: C₇H₁₅O₄P
• 分子量: 194.167
• InChiKey: WZXHAJJSRFWHIL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.45
• 重原子数：
  12.0
• 可旋转键数：
  5.0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  52.6
• 氢给体数：
  0.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  methyl 3-(isopropoxyhydrophosphoryl)propanoate 、 sodium isopropylate 、 丙烯酸甲酯（MA） 以 异丙醇 为溶剂， 生成 isopropoxy-3-carbisopropoxy-1-oxophosphorinan-4-one 、 diisopropyl 3,3'-(isopropoxyphosphoryl)dipropanoate
  参考文献：
  名称：

  Novel Cyclic Phosphinic Acids as GABA_C ρ Receptor Antagonists: Design, Synthesis, and Pharmacology

  摘要：

  Understanding the role of GABA(C) receptors in the central nervous system is limited due to a lack of specific ligands. Novel gamma-aminobutyric acid (GABA) analogues based on 3-(aminomethyl)-1-oxo-1-hydroxy-phospholane 17 and 3-(guanido)-1-oxo-1-hydroxy-phospholane 19 were investigated to obtain selective GABA(C) receptor antagonists. A compound of high potency (19, K-B = 10 mu M) and selectivity (greater than 100 times at rho(1) GABA(C) receptors as compared to alpha(1)beta(2)gamma(2L) GABA(A) and GABA(B(1b,2)) receptors) was obtained. The cyclic phosphinic acids (17 and 19) are novel lead agents for developing into more potent and selective GABA(C) receptor antagonists with increased lipophilicity for future in vivo studies.

  DOI：

  10.1021/ml1001344
• 作为产物：
  描述：

  isopropyl phosphinate 、 丙烯酸甲酯（MA） 在 N,N-二异丙基乙胺 作用下， 以 水 、 乙腈 为溶剂， 以9.15 g的产率得到methyl 3-(isopropoxyhydrophosphoryl)propanoate
  参考文献：
  名称：

  Novel Cyclic Phosphinic Acids as GABA_C ρ Receptor Antagonists: Design, Synthesis, and Pharmacology

  摘要：

  Understanding the role of GABA(C) receptors in the central nervous system is limited due to a lack of specific ligands. Novel gamma-aminobutyric acid (GABA) analogues based on 3-(aminomethyl)-1-oxo-1-hydroxy-phospholane 17 and 3-(guanido)-1-oxo-1-hydroxy-phospholane 19 were investigated to obtain selective GABA(C) receptor antagonists. A compound of high potency (19, K-B = 10 mu M) and selectivity (greater than 100 times at rho(1) GABA(C) receptors as compared to alpha(1)beta(2)gamma(2L) GABA(A) and GABA(B(1b,2)) receptors) was obtained. The cyclic phosphinic acids (17 and 19) are novel lead agents for developing into more potent and selective GABA(C) receptor antagonists with increased lipophilicity for future in vivo studies.

  DOI：

  10.1021/ml1001344